Recent Advances in ARDS and Sepsis

Sepsis: 2026 Surviving Sepsis Campaign (SSC) Guidelines

• Stratified antibiotic timing (a major shift from the old "1-hour bundle for everyone"): patients in septic shock still get antimicrobials immediately; those with probable/definite sepsis without shock get them within 3 hours after a brief diagnostic evaluation; low-suspicion patients can have therapy deferred with close monitoring. This replaces the blanket "give antibiotics within 1 hour" approach criticized for driving antibiotic overuse.
• Screening tools: stronger move away from qSOFA as a primary screening tool.
• Prehospital care: suggests antimicrobial therapy en route (ambulance/flight) when transport time to hospital exceeds 60 minutes in septic shock.
• Fluid management: new emphasis on active fluid removal/de-resuscitation after the acute resuscitation phase, and updated guidance on resuscitation fluid choice.
• Blood pressure targets in older adults: individualized MAP targets rather than a single universal number.
• Sepsis-associated respiratory failure: for hypoxemic respiratory failure without ARDS, a suggested tidal volume of 6-8 mL/kg IBW versus a lower 4-<6 mL/kg IBW strategy, plus a strong push for routine screening for ARDS development since it is frequently missed or diagnosed late in septic patients.
• Supportive care: PPI stress-ulcer prophylaxis in high GI-bleed-risk patients, a recommendation against probiotics, and continuity-of-care additions covering post-discharge psychological and physical rehabilitation.
• Glucose threshold for starting insulin (≥180 mg/dL) is unchanged from 2021.

• SEP-1 bundle compliance is associated with reduced hospital mortality, though causal strength is debated - Ford et al. 2025 [PMID: 39961104].
• Sepsis alert/screening systems in emergency departments improve guideline adherence and are associated with lower mortality - Kim et al., JAMA Network Open 2024 [PMID: 39037814].
• A critical appraisal (AGREE II) found substantial quality variability across global sepsis infection-management guidelines, underscoring implementation gaps outside high-resource settings [PMID: 39984828].
• Temperature-management meta-analyses in 2025 have not shown a clear survival benefit for targeted hypothermia in sepsis over usual care [PMID: 40257365].

ARDS: Precision Medicine and Phenotype-Guided Care

• Hyperinflammatory vs hypoinflammatory subphenotypes, first described via biomarker clustering, remain the most reproducible ARDS classification and are increasingly proposed as an enrichment strategy for clinical trials, though a 2025 review cautions that heterogeneity in derivation cohorts and biomarker panels still limits bedside utility (MDPI review, 2025).
• Proteomic phenotyping: a large-scale blood proteomics study (2026, European Respiratory Journal) identified distinct inflammatory endotypes with different imaging patterns and prognoses, pushing toward molecularly defined ARDS subtypes rather than purely clinical (Berlin) criteria.
• Open-source phenotype classifiers: Pensier and colleagues (2025, Intensive Care Medicine) released a validated open-source clinical classifier to make phenotype assignment usable in real time rather than only in retrospective trial cohorts.
• Imaging/lung-morphology-guided ventilation: CT- and electrical-impedance-tomography (EIT)-based approaches are being used to individualize PEEP titration and detect ventral-dorsal or left-right ventilation asymmetry, allowing more mechanistically tailored recruitment/PEEP strategies (Nazarian, Bos, Smit - Current Opinion in Critical Care, 2026; Sun et al., EIT phenotyping, 2026).
• Lung-ultrasound-guided personalized ventilation pilot RCT (Sinnige et al., 2025) is testing whether bedside ultrasound can replace CT/EIT for individualizing ventilator settings.
• Driving pressure, transpulmonary pressure, and mechanical power-based personalization: a 2024 systematic review/meta-analysis found these physiology-based targets outperform fixed low-tidal-volume protocols alone in reducing ventilator-induced lung injury risk [PMID: 39214040].
• Prone positioning refinement: newer data show prone position's benefit on ventilation-perfusion matching varies by clinical phenotype, suggesting prone positioning may need to be targeted rather than applied uniformly to all moderate-severe ARDS [PMID: 40022116].
• Adjunct therapies: recent meta-analyses on early neuromuscular blockade and continuous renal replacement therapy in ARDS have generally failed to show consistent mortality benefit, reinforcing that supportive care (lung-protective ventilation, conservative fluids, prone positioning in appropriate phenotypes) remains the backbone rather than any single pharmacologic adjunct.

Bottom Line